Lexicon Pharmaceuticals
LXRX
123 hedge funds and large institutions have $438M invested in Lexicon Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 54 increasing their positions, 21 reducing their positions, and 7 closing their positions.
1,357% more capital inflows, than outflows
Capital inflows: $131M | Capital outflows: $8.96M
271% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 7
157% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 21
18% more funds holding
Funds holding: 104 → 123 (+19)
12.47% more ownership
Funds ownership: 77.15% → 89.62% (+12%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
62% less call options, than puts
Call options by funds: $506K | Put options by funds: $1.34M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
+$73.7M |
| 2 |
BVF Inc
San Francisco,
California
|
+$10.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.68M |
| 4 |
Millennium Management
New York
|
+$6.93M |
| 5 |
Octagon Capital Advisors
New York
|
+$5.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$4.59M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.25M |
| 3 |
JP Morgan Chase
New York
|
-$995K |
| 4 |
Renaissance Technologies
New York
|
-$641K |
| 5 |
Fisher Asset Management
Camas,
Washington
|
-$335K |
LXRX Hedge Fund Activity: Q2 2023 in Review
123 of the 6,389 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q2 2023, worth a combined $438M — up 24% from $354M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new LXRX positions and 7 closed out — a net gain of 19 holders — while 54 added to existing stakes and 21 trimmed.
The largest buyer was Artal Group, adding an estimated $73.7M. The largest seller was D.E. Shaw & Co, cutting an estimated $4.59M.
- 123 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q2 2023, up from 104 in Q1 2023.
- Funds reported $438M of Lexicon Pharmaceuticals stock for Q2 2023, up 24% quarter-over-quarter.
- 26 funds opened new Lexicon Pharmaceuticals positions in Q2 2023 and 7 closed out, a net change of +19 holders.
- The largest Lexicon Pharmaceuticals buyer in Q2 2023 was Artal Group, an estimated $73.7M added.
- The largest Lexicon Pharmaceuticals seller in Q2 2023 was D.E. Shaw & Co, an estimated $4.59M sold.
Based on aggregated 13F filings for Q2 2023.